Oddi, Sergio http://orcid.org/0000-0002-6217-698X
Scipioni, Lucia
Totaro, Antonio
Angelucci, Clotilde
Dufrusine, Beatrice
Sabatucci, Annalaura
Tortolani, Daniel
Coletta, Isabella
Alisi, Maria Alessandra
Polenzani, Lorenzo
Assfalg, Michael
Caltagirone, Carlo
Dainese, Enrico http://orcid.org/0000-0001-7163-9344
Maccarrone, Mauro http://orcid.org/0000-0002-3990-2963
Funding for this research was provided by:
Angelini Pharma (ACRAF01, ACRAF01)
Article History
Received: 5 July 2019
Accepted: 7 October 2019
First Online: 22 October 2019
Competing interests
: I.C., M.A.A. and L.P. were employed by Angelini at the time of manuscript preparation and submission. Angelini did not influence experimental design nor interpretation of results. C.C. was the Scientific Director of the Institute, and M.M. was the Director of the Research Unit that received funding from Angelini to explore molecular mechanisms of action of bindarit. The remaining authors declare that no competing - both financial and non-financial - interests exist.